Medicine and Pharmacy Reports最新文献

{"title":"Raising public awareness of the pharmacists' involvement in the fight against the COVID-19 pandemic - the effects of Pharmacy Heroes campaign.","authors":"Piotr Merks, Marta Jakubowska, Ewelina Drelich, Urszula Religioni, Damian Świeczkowski, Jędrzej Lewicki, Justyna Strocka, Sebastian Grochala, Wioleta Gołebiewska, Regis Vaillancourt","doi":"10.15386/mpr-2718","DOIUrl":"10.15386/mpr-2718","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic has significantly impacted health systems around the world. The healthcare burden was visible in all countries struggling with the pandemic. Pharmacists, who are at the frontline beating the COVID-19 pandemic, played a significant role in relieving the burden on healthcare systems. However, the role of pharmacists in the fight against the COVID-19 pandemic was not appreciated. Therefore, our goal was to create the Pharmacy Heroes initiative, which brings together pharmacists from around the world during the COVID-19 pandemic and promotes the role of pharmacists in the health care system.</p><p><strong>Aim: </strong>The article aims to present the results of the Pharmacy Heroes campaign, mainly in terms of dissemination.</p><p><strong>Results: </strong>85 countries from six continents were involved in the Pharmacy Heroes campaign. Pharmacists who joined the campaign worked in both community and hospital pharmacies.</p><p><strong>Conclusion: </strong>The Pharmacy Heroes campaign showed the significant commitment of pharmacists around the world. Being the third-largest group of medical professionals, pharmacists played a crucial role in fighting the COVID-19 pandemic.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"392-397"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do positive bile cultures influence morbidity and mortality after duodenopancreatectomy?","authors":"Cristian Liviu Cioltean, Dana Iancu, Cornel Iancu","doi":"10.15386/mpr-2812","DOIUrl":"10.15386/mpr-2812","url":null,"abstract":"<p><strong>Background and aims: </strong>Bacterobilia is associated with postoperative morbidity after pancreatico-duodenectomy (PD), mostly due to infectious complications. Investigating the frequency of bacterial species isolated from intraoperative biliary cultures and associated problems following PD was the goal of this study.</p><p><strong>Methods: </strong>The frequency of isolated bacterial species and surgical complications were evaluated using an ANOVA test. The relationship between biliary cultures and each of the following complications: delayed gastric emptying (DGE), post-operative pancreatic fistula (POPF), biliary fistula and surgical site infectious (SSIs) were evaluated by using the odds ratio.</p><p><strong>Results: </strong>In 340/513 (66%) of the PDs, positive biliary cultures were discovered. In patients with complications following surgery, different polymicrobial biliary cultures were shown to be more prevalent. A noteworthy incidence of biliary cultures confirming the presence of E. Coli, Klebsiella pneumoniae, and Enterococcus fæcalis (p < 0.001) was noted in SSIs (surgical site infectious). There was a strong correlation (p < 0.001) between the prevalences of polymicrobial biliary cultures containing Escherichia coli, Klebsiella pneumoniæ, Enterococcus fæcalis, and Enterococcus fæcium and POPF. Higher incidence of intra-abdominal collection and DGE was observed in biliary cultures positive for Escherichia coli, Enterococcus fæcalis, and Enterococcus fæcium (p < 0.001). Notably, as a distinct complication, Escherichia coli was substantially linked to DGE (p < 0.01).</p><p><strong>Conclusion: </strong>While monomicrobial Escherichia coli bacterobilia is linked to DGE as a distinct consequence following PD, specific prevalences of polymicrobial bacterobilia are related with severe complications.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"381-386"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanovaccine targeting in colorectal cancer: a multi-dataset analysis of CEA expression, cytokine profiles, and co-expressed genes.","authors":"Razvan-Septimiu Zdrehus, Cristina Mitrea, Lucian Mocan","doi":"10.15386/mpr-2917","DOIUrl":"10.15386/mpr-2917","url":null,"abstract":"<p><strong>Background: </strong>Carcinoembryonic antigen (CEA/CEACAM5) is a well-established tumor-associated antigen overexpressed in epithelial malignancies, including colorectal cancer (CRC). While its diagnostic and therapeutic relevance is recognized, its immunological context and potential as a nanovaccine target remain underexplored.</p><p><strong>Aim: </strong>This study aims to enable the rational design and refinement of CEA-based nanovaccines by integrating transcriptomic and spatial data to identify immunologically relevant co-expressed biomarkers and potential therapeutic targets.</p><p><strong>Methods: </strong>We conducted an integrative bioinformatics analysis using transcriptomic data from TCGA-COAD, GEO, and spatial datasets (GSE207843, GSE226997), complemented by differential gene expression analysis (GSE245218). CEACAM5 expression was correlated with cytokine profiles (IL10, IFNG, TNF, IL1B, IL12A, IL4), immune cell infiltration (via xCell), and co-expression networks. Genes with Spearman ρ > 0.75 were prioritized as vaccine candidates and evaluated through oncofetal expression and literature curation.</p><p><strong>Results: </strong>CEACAM5 expression was inversely correlated with IFNG, IL10, TNF, and IL1B, suggesting a potential immunosuppressive phenotype. xCell analysis revealed negative trends between CEACAM5 and effector immune populations including CD8⁺ T cells and NK cells. Spatial transcriptomics confirmed CEACAM5 compartmentalization in tumor epithelium with minimal cytokine overlap. Co-expression analysis identified EPCAM and ATP10B as high-confidence candidates. Embryonic vs. adult differential analysis (GSE245218) confirmed their oncofetal expression patterns. Gene ontology analysis revealed downregulation of antibacterial humoral immune pathways.</p><p><strong>Conclusion: </strong>CEACAM5 defines a distinct immune-silent tumor phenotype and co-localizes with other vaccine-relevant genes such as EPCAM. This study provides a comprehensive immunogenomic rationale for CEACAM5-directed nanovaccine development and proposes EPCAM and ATP10B as co-targets based on tumor-specific and developmental expression profiles.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"358-370"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-assessment of P.O.C.U.S. use in the clinical practice of anesthesia and intensive care by medical residents after completion of simulation training on a high-fidelity simulator.","authors":"Robert Simon, Cristina Petrisor, Constantin Bodolea, Oana Antal, Horatiu Nicolae Vasian, Ion Cosmin Puia","doi":"10.15386/mpr-2902","DOIUrl":"10.15386/mpr-2902","url":null,"abstract":"<p><strong>Background: </strong>Simulation based education and training (SBET) is an important part of formal medical education and training, with anesthesia and intensive care domains being among the first to use this teaching method. Implementation of SBET into anesthesia and intensive care training is included in the recommendations lists of the European Society of Anesthesia and Intensive Care, with Point of Care Ultrasound (POCUS) being on the list of procedures that residents should be trained in using SBET.</p><p><strong>Objectives: </strong>In this study the objective is to assess the clinical use of POCUS by trainees in Anesthesia and Intensive Care that finished a simulation program on a high-fidelity simulator.</p><p><strong>Methods: </strong>We developed a questionnaire comprised of seven sections that evaluates the use of POCUS in clinical practice related to airway, lung, cardiac ultrasound, the availability of POCUS, possible barriers that create limitations, as well as scoring and feedback regarding the simulation sessions and distributed it to trainees that finished the simulation sessions.</p><p><strong>Results: </strong>Over 90% of respondents declare using POCUS in their daily clinical practice, with more use of pulmonary evaluations than cardiac evaluations. Most of the responders declared good or very good knowledge and ability to diagnose most of the critical conditions described in the curriculum for lung and cardiac POCUS.</p><p><strong>Conclusions: </strong>Self-assessment methods may be used alongside traditional methods to offer a wider view on POCUS competency and maintenance of skills of trainees in anesthesia and intensive care.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"300-310"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Irritable bowel syndrome after <i>Clostridioides difficile</i> infection.","authors":"Teodora Iacob, Giuseppe Guido Maria Scarlata, Ludovico Abenavoli, Daniel-Corneliu Leucuţa, Mihaela S Lupşe, Dan L Dumitraşcu","doi":"10.15386/mpr-2832","DOIUrl":"10.15386/mpr-2832","url":null,"abstract":"<p><strong>Background: </strong>Irritable bowel syndrome (IBS) is a chronic functional disorder characterized by abdominal pain, bloating, and altered bowel habits. Post-infectious IBS (PI-IBS) develops after acute gastroenteritis, including <i>Clostridioides difficile</i> infection (CDI). While CDI has been shown to decrease in prevalence during the pandemic era, studies indicate a substantial risk of PI-IBS following CDI, data remaining limited. The aim of the present study was to evaluate the risk of PI-IBS following a CDI and a potential correlation between PI-IBS onset and the severity of CDI.</p><p><strong>Methods: </strong>This cross-sectional study included 69 patients hospitalized with suspected CDI at a tertiary center for Infectious Diseases, in Romania. Inclusion criteria were: patients >18 years of age with confirmed CDI via polymerase chain reaction. The severity of CDI was assessed based on hospitalization, laboratory parameters, and clinical symptoms. PI-IBS was evaluated six months after CDI using the Rome IV IBS questionnaire and the Bristol Stool Form Scale. Relative risk (RR) was calculated using SPSS software and a p value <0.05 was considered significant.</p><p><strong>Results: </strong>Among the 38 enrolled patients, 24/38 (63%) were males, while 14/38 (37%) were females. The CDI was confirmed in 14/38 (37%) patients by PCR and the infection was ruled out in 24/38 (63%) patients (control group). PI-IBS developed in 57% of the CDI group compared to 25% in the control group (RR=2.29, 95% CI 0.99-5.23, <i>p=</i>0.04). CDI severity correlated with higher PI-IBS risk, with 90% of hospitalized CDI patients developing PI-IBS (RR=2.72, <i>p=</i>0.0493).</p><p><strong>Conclusion: </strong>PI-IBS occurred in over half of the patients six months after CDI, with disease severity increasing the PI-IBS risk. These findings highlight the need for proactive management in severe CDI cases to prevent long-term gastrointestinal complications.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"320-324"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polymorphous adenocarcinoma: a review of the literature and presentation of a case in an uncommon anatomical area.","authors":"Bogdan Andrei Bumbu, Mădălina Anca Moldovan, Iuliu George Moldovan, Alexandru Iosif Precup, Raluca Ortensia Iurcov","doi":"10.15386/mpr-2882","DOIUrl":"10.15386/mpr-2882","url":null,"abstract":"<p><strong>Background: </strong>Polymorphous adenocarcinoma (PAC) is a type of salivary gland tumor that is rare and diverse in morphology. It is typically found in the minor salivary glands, with the palate being the most common location. However, this tumor is often misunderstood, underdiagnosed, and controversial in nomenclature. Its low-grade behavior may be unpredictable, making it challenging to manage.</p><p><strong>Case report: </strong>In this paper, we detail a case of PAC that developed in the buccal mucosa, which is a less common anatomical location. We discuss the patient's clinical presentation, imaging findings, histological examination results, as well as the surgical treatment and follow-up outcomes. We also examine relevant literature related to the topic to provide a comprehensive understanding of this rare case.</p><p><strong>Conclusions: </strong>Although complete surgical excision is the primary management for PAC, there is no gold standard treatment for it. It is crucial to follow up on patients with PAC in the long term, as recurrences, lymph nodes, and distant metastasis, even rare, may impair the prognosis in certain patients.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"403-408"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exclusive enteral nutrition in Crohn's disease pediatric patients: from clinical remission to transmural healing.","authors":"Georgia Valentina Tartamus Tita, Daniela Elena Serban, Lacramioara Eliza Chiperi, Cristina Rebeca Fogas, Stefana Arlinda Medan, Vasile Marcel Tantau","doi":"10.15386/mpr-2900","DOIUrl":"10.15386/mpr-2900","url":null,"abstract":"<p><strong>Background and aims: </strong>Exclusive enteral nutrition (EEN) is a well-established first-line therapy for inducing remission in mild-to-moderate pediatric Crohn's disease (pCD). While clinical remission (CR) and mucosal healing (MH) are widely accepted therapeutic goals, the concept of transmural healing (TH) has gained increasing recognition. This study aimed to evaluate the effectiveness of EEN in pCD patients from Romania, focusing on nutritional status, remission outcomes, and the impact of various factors on treatment efficacy.</p><p><strong>Methods: </strong>We conducted a retrospective observational study of pCD consecutive patients who received EEN for induction of remission between 2007 and 2017 at a referral center in Cluj-Napoca, Romania. CR was defined as a weighted Pediatric Crohn's Disease Activity Index (wPCDAI) <12.5, MH as a fecal calprotectin level <250 microg/g, and TH as the combination of MH and imagistic remission assessed by intestinal ultrasonography. Statistical analyses included descriptive and comparative approaches, including logistic regression, with p <0.05 considered significant.</p><p><strong>Results: </strong>Twenty patients with pCD, representing 45% of the cohort, were included. The median age at diagnosis was 14.2 years (9.9-18.4), and 65% were male. EEN was administered with a mean duration of 7.84±1.26 weeks. Body mass index Z-scores significantly improved following EEN (p=0.02). Hypoalbuminemia, detected in 55% of patients at diagnosis, resolved completely after EEN (p=0.00015). CR was achieved in 82% of patients with active clinical disease, MH in 26% of patients with microscopic activity, and TH in 20% of patients with imagistic activity. Age at diagnosis, disease behavior, location, activity, and anti-Saccharomyces cerevisiae antibody status were not significantly associated with CR or MH. Disease activity at initiation, measured by the wPCDAI, was inversely associated with TH (p=0.004).</p><p><strong>Conclusions: </strong>This is the first study to report on EEN outcomes in pCD patients from Romania. EEN was effective in improving nutritional status and inducing CR, while MH was achieved in about one-quarter of patients. TH was also observed, though less frequently, and was negatively associated with higher baseline clinical disease activity. Regional factors may have influenced these outcomes.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"371-380"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New prospects in oncotherapy: bioactive compounds from <i>Taraxacum officinale</i>.","authors":"Daniel Cord, Mirela Claudia Rîmbu, Liliana Popescu","doi":"10.15386/mpr-2875","DOIUrl":"10.15386/mpr-2875","url":null,"abstract":"<p><p>Cancer remains one of the most significant global health challenges, requiring continuous exploration of novel therapeutic agents. Traditional medicine has long used <i>Taraxacum officinale H.Wigg</i>, commonly known as dandelion, for its diverse pharmacological properties. Recent studies have highlighted its potential anticancer effects attributed to a rich phytochemical profile containing flavonoids, terpenoids, phenolic acids, polysaccharides, and sterols. This review systematically examines the available scientific literature regarding <i>Taraxacum officinale</i>, focusing on its ethnomedical application, phytochemical composition, and anticancer mechanism demonstrated <i>in vitro</i> and <i>in vivo</i> models. Key bioactive compounds, such as taraxasterol, chlorogenic acid, chicoric acid, and taraxinic acid, have been identified as promising agents capable of inhibiting tumor cell proliferation and modulating oncogenic pathways. Additionally, the plant's safety profile and toxicological assessments are discussed to evaluate its therapeutic viability. Given its multi-target biological activity and low toxicity, <i>Taraxacum officinale</i> holds significant potential for integration into oncotherapy as an adjuvant treatment. However, further preclinical and clinical investigations remain essential to validate its efficacy and mechanism of action, paving the way for the development of cost-effective, plant-based cancer therapeutics.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"290-299"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of steroids and antiviral agents in the treatment of Bell's palsy.","authors":"Christos Sialakis, Aikaterini Frantzana, Christos Iliadis, Peter Ouzounakis, Lambrini Kourkouta","doi":"10.15386/mpr-2786","DOIUrl":"10.15386/mpr-2786","url":null,"abstract":"<p><strong>Background: </strong>This study aims to investigate the effectiveness of steroids plus antivirals versus steroids alone in the treatment of Bell's palsy. Due to conflicting results in the existing literature, we conducted this meta-analysis to synthesize the available evidence and extract a more complete conclusion.</p><p><strong>Methods: </strong>We searched electronic databases PubMed, CINAHL, ScienceDirect, MEDLINE, OVID, and Scopus. The last search was performed on March 2024. In this study, 7 randomized controlled trials were included. We used random and fixed effects for sensitivity analysis for each outcome, and we further proceeded to perform a Bayesian meta-analysis using priors and calculate the posterior distribution.</p><p><strong>Results: </strong>Performing frequentist meta-analysis, both the random and fixed effects showed statistical significance, indicating the superiority of the combination treatment. The random log odds ratio was 0.5865 [95% CI: 0.0141 to 1.1589 and the Back-Transform Log Odds Ratio to Odds Ratio was 1.798 [95% CI: 1.014 to 3.186]. The fixed effect log odds ratio was 0.4377 [95%CI: 0.0819 to 0.7934] and the Back-Transform Log Odds Ratio to Odds Ratio was 1.549 [95% CI:1.085 to 2.211]. Neither the rank correlation nor the regression test in both models indicated any funnel plot asymmetry and publication bias.Performing Bayesian meta-analysis, in the posterior distribution the model-averaged log odds ratio was 0.26 [0.00 to 0.90], showing no statistically significant results, as the log odds ratio contains the zero. The inclusion Bayes Factor (BF) for the effect was 1.225 showing anecdotal supporting evidence for the combination treatment. The inclusion BF for the heterogeneity was 0.979, showing no support for its existence in the analysis and the inclusion BF for the publication bias was 0.622, a lower of 1, indicating evidence of its absence in the analysis.</p><p><strong>Conclusions: </strong>The combination of steroids plus an antiviral agent, is more efficacious than steroid monotherapy in treating Bell's palsy. This conclusion is supported by frequentist analysis, but not by the Bayesian approach as the Bayesian meta-analysis was inconclusive, suggesting some uncertainty in the effect size but this could be due to priors influence. Further research with advanced syntheses such as network and Bayesian meta-analysis is needed as well as more double-blinded randomized controlled trials.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"267-282"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between metabolic syndrome and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus: a cross-sectional study.","authors":"Abdessamad Malki, Imane Assarrar, Imane Ziani, Fatim Zahra Bentebbaa, Nisrine Bouichrat, Siham Rouf, Hanane Latrech","doi":"10.15386/mpr-2779","DOIUrl":"10.15386/mpr-2779","url":null,"abstract":"<p><strong>Background and aims: </strong>Diabetic peripheral neuropathy (DPN) is the most prevalent chronic complication of diabetes. Several risk factors have been identified in recent studies, in particular metabolic syndrome (MetS). However, this association remains unclear. We aimed to determine the prevalence of DPN and to study its associated factors, especially the MetS as a potential risk factor of DPN in patients with Type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>This was a retrospective and comparative study, with cross-sectional collected data, involving patients with T2DM from North Africa, followed up in the Department of Endocrinology-Diabetology-Nutrition at Mohammed VI University Hospital Center of Oujda, located in the eastern region of Morocco. Patients were grouped according to the presence (T2DM/DPN+, n = 110) or absence of DPN (T2DM/DPN-, n = 290). Data were collected from medical records and analyzed using SPSS software version 21.</p><p><strong>Results: </strong>DPN was found in 27.5% of the patients. The mean age was similar between the two groups, at 58.96 ± 11.86 years in the T2DM/DPN+ group and 57.10 ± 13.29 years in the T2DM/DPN- group. Males comprised 40.9% of the T2DM/DPN+ group and 31.7% of the T2DM/DPN- group, but this difference was not statistically significant (p = 0.054). Patients with DPN had a significantly longer duration of diabetes (median 10 years vs. 5 years, p < 0.001). Both groups showed glycemic imbalance, with mean HbA1c values of 10.71 ± 2.31% for T2DM/DPN+ and 10.40 ± 2.87% for T2DM/DPN-, without a significant difference. MetS was a significant predictor of neuropathy presence. The prevalence of DPN was greater in individuals with hypertension (p = 0.013), abdominal obesity (p = 0.010), elevated triglyceride levels (p = 0.007), and low HDLc (p = 0.013). Male sex and the duration of diabetes were found to be significant risk factors for the development of DPN.</p><p><strong>Conclusion: </strong>MetS and its components are strongly associated with the presence of DPN in patients with T2DM. Therefore, screening and optimal control of these risk factors may help prevent DPN in these patients. However, further intervention studies are needed to determine whether comprehensive multifactorial control in patients with T2DM and MetS can effectively prevent DPN.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"342-348"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}